ssao

SSAO inhibitor-2 (Compound 1) can be used in the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc. SSAO inhibitor-2 is the inhibitor of semicarbazide-sensitive amine oxidase (SSAO) with IC 50 s <10 nM and 10-100 μM for human SSAO and MAO-A, respectively [1].

SSAO/VAP-1 Inhibitor 1 is a potent compound aimed at inhibiting SSAO/VAP-1, a protein involved in facilitating the translocation of Glucose Transport 4 (GLUT 4) to the cell membrane in adipocytes, thus playing a crucial role in glucose regulation. Additionally, in endothelial cells, this enzyme is responsible for mediating the adherence and infiltration of leukocytes, contributing to inflammatory responses. Given these mechanisms, SSAO/VAP-1 Inhibitor 1 holds considerable potential for research into treatments for inflammation, inflammation-related conditions, diabetes, and diabetes-associated diseases[1].

SSAO inhibitor-3 (Compound 2) can be used in the study of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc. SSAO inhibitor-3 is an inhibitor of semicarbazide-sensitive amine oxidase (SSAO) with IC 50 s of 0.1-10 μM and <10 nM for human AOC1 and SSAO, respectively [1].

SSAO inhibitor-1 is a compound that acts as an inhibitor of semicarbazide-sensitive amine oxidase (SSAO). It exhibits anti-inflammatory properties and is commonly employed in research pertaining to liver diseases.

BI-1467335 HCl(BI 1467335) is a selective, orally active inhibitor of semicarbazide-sensitive amine oxidase (SSAO) that helps improve chronic obstructive pulmonary disease in mice[2].

MDL-72274 HCl is a selective and effective inhibitor of SSAO for the treatment of Parkinson's disease.

MD 220661 is an inhibitor of semicarbazide-sensitive amine oxidase (SSAO), and a substrate of the enzyme.

PXS-4681A is a powerful, specific, and irreversible inhibitor of semicarbazide-sensitive amine oxidase (SSAO; VAP-1), with an oral activity and a Ki value of 37 nM. It exhibits exceptional selectivity towards related amine oxidases, ion channels, and seven-transmembrane domain receptors. Additionally, PXS-4681A demonstrates potent anti-inflammatory properties.